|
|
||||||||


* Division of Immunology, Howard Hughes Medical Institute, Memorial Sloan-Kettering Cancer Center, New York, NY 10021; and
Division of Immunology, Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720
CTLA-4 has been shown to be an important negative regulator of T cell activation. To better understand its inhibitory action, we constructed CTLA-4 transgenic mice that display constitutive cell surface expression of CTLA-4 on CD4 and CD8 T cells. In both in vivo and in vitro T cell responses, CTLA-4 overexpression inhibits T cell activation. This inhibition is dependent on B7 and CD28, suggesting that overexpressed CTLA-4 inhibits responses by competing with CD28 for B7 binding or by interfering with CD28 signaling. In addition, expression of the transgene decreases the number of CD25+Foxp3+ T cells in these mice, but does not affect their suppressive ability. Our data confirm the activity of CTLA-4 as a negative regulator of T cell activation and that its action may be by multiple mechanisms.
This article has been cited by other articles:
![]() |
W. A. Teft and J. Madrenas Molecular Determinants of Inverse Agonist Activity of Biologicals Targeting CTLA-4 J. Immunol., September 15, 2007; 179(6): 3631 - 3637. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Pan, M. M. Winslow, L. Chen, A. Kuo, D. Felsher, and G. R. Crabtree Enhanced NFATc1 Nuclear Occupancy Causes T Cell Activation Independent of CD28 Costimulation J. Immunol., April 1, 2007; 178(7): 4315 - 4321. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |